Earnings call transcript: Danaher tops Q3 2026 estimates but shares fall premarket

Danaher reported Q3 2026 adjusted EPS of $2.11 versus $1.92 expected and revenue of $6.6 billion versus $6.56 billion, while core revenue growth excluding respiratory improved to 5.5%. It raised full-year adjusted EPS guidance to $8.57-$8.62 from $8.45-$8.60, but respiratory sales of about $350 million reduced reported core growth by roughly 250 bps, and its preliminary 2027 growth starting point is 4%-5% excluding respiratory. Shares fell 3.67% in premarket trading to $216, reflecting a cautious investor response despite the earnings beat and higher guidance.

Analysis

The market is marking down the quality and durability of growth, not the quarter’s execution. Ex-respiratory growth is improving, but management’s 2027 starting point does not yet imply acceleration; meanwhile, reported growth remains exposed to a volatile respiratory base. That limits the case for paying up for a recovery before it is visible in segment results. The EPS beat also deserves a quality adjustment: operational execution helped, but tariff refunds provided a modest tailwind, so investors should distinguish repeatable productivity from one-off support.

The most useful upside signal is bioprocessing order momentum, but orders are a lead indicator, not revenue. Watch conversion into shipments and consumables demand over the next two quarters; if it slips, the growth narrative may outrun fundamentals. Longer term, Danaher’s connected selling and autonomous-lab strategy could raise customer retention and cross-business share, but current AI benefits are described as modest. NVIDIA may gain ecosystem credibility from the collaboration, not a material near-term earnings driver.

Near term, DHR remains vulnerable to multiple compression if January guidance merely confirms a 4%-5% trajectory. Over 6-18 months, stronger share gains, bioprocessing conversion, or evidence that commercial integration lifts organic growth could reverse that pressure. Respiratory seasonality is a separate swing factor, not proof of broad demand recovery.

Key Decisions for Investors

• Do not chase the earnings beat. Keep DHR at an underweight versus a diversified life-science-tools exposure until the January outlook clarifies whether underlying growth can accelerate; avoid an outright short absent peer valuation and estimate-revision data.
• Use bioprocessing as the principal 1-3 month confirmation test: monitor orders converting into revenue, especially upstream consumables and resins. Reassess the underweight if conversion supports growth above the current 4%-5% framework; worsening conversion or a lower outlook would strengthen the cautious thesis.
• Treat respiratory revenue as a volatility overlay, not a core thesis. Track infection trends and actual sales against management’s 2027 starting assumption; a materially weaker season could pressure reported growth, while a stronger season may lift results without validating non-respiratory acceleration.
• Keep the NVIDIA collaboration out of near-term earnings estimates. Revisit only if Danaher reports measurable instrument/software attach, customer adoption, or revenue contribution; absent that evidence, the partnership is strategic optionality rather than a standalone NVDA or DHR catalyst.